EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)

Inclusion Criteria:

• Non-dialyzed male or female patients with CKD, with a GFR of less than 30mL/min/1.73m²who have elevated serum phosphorus or who develop elevated serum phosphorus followingwashout from phosphorus-binding therapy.

• Patients must have written informed consent

• Negative serum pregnancy test if appropriate

• Expected to be able to comply with protocol procedures and schedule

Exclusion Criteria:

• Unstable angina pectoris

• Severe congestive heart failure

• Severe liver dysfunction

• Severe malnutrition

• Severe hyperparathyroidism

• AIDS (HIV positive subjects without AIDS are not excluded)

• Active malignancy for which the subject is receiving chemotherapy or radiation

• Subject unlikely to complete the study

• History of obstructed bowels or hypersensitivity to any of the study medications ortheir components

• History of swallowing disorders such as dysphagia (that would prevent the subject fromtaking the study drug) severe gastrointestinal motility disorders, or major GI tractsurgery

• Participation in an investigational drug or device trial within 30 days ofrandomization

• Subjects on Vitamin D therapy

• Subjects with acute symptoms, in the last month, or current radiographic evidence ofkidney stones

• Subjects who have undergone renal transplant or receiving dialysis

• Or any condition with makes patient participation not in the patients best interest